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Growing evidence suggests that hepatic-insulin resistance is sufficient to promote progression 
to cardiovascular disease. We have shown previously that liver-specific protein-tyrosine-
phosphatase 1B (PTP1B) deficiency improves hepatic-insulin sensitivity and whole-body 
glucose homeostasis. The aim of this study was to investigate the impact of liver-specific 
PTP1B-deficiency (L-PTP1B-/-) on cardiac and peripheral vascular function, with special 
emphasis on endothelial function in the context of high-fat diet (HFD)-induced obesity. 
L-PTP1B-/- mice exhibited an improved glucose and lipid homeostasis and increased insulin 
sensitivity, without changes in body weight. HFD-feeding increased systolic blood pressure 
(BP) in both L-PTP1B-/- and control littermates; however, this was significantly lower in L-
PTP1B-/- mice. HFD-feeding increased diastolic BP in control mice only, whilst the L-PTP1B-
/- mice were completely protected. The analysis of the function of the left ventricle (LV) 
revealed that HFD-feeding decreased LV fractional shortening in control animals, which was 
not observed in L-PTP1B−/− mice. Importantly, HFD feeding significantly impaired 
endothelium-dependent vasorelaxation in response to acetylcholine in aortas from control 
mice, whilst L-PTP1B−/− mice were fully protected. This was associated with alterations in 
eNOS phosphorylation. Selective inhibition of COX-2, using NS-398, decreased the 
contractile response in response to serotonin (5-HT) only in vessels from control mice. HFD-
fed control mice released enhanced levels of prostaglandin E, a vasoconstrictor metabolite; 
whilst both chow- and HFD-fed L-PTP1B−/− mice released higher levels of prostacylin, a 
vasorelaxant metabolite.  
Our data indicate that hepatic-PTP1B inhibition protects against HFD-induced endothelial 
dysfunction, underscoring the potential of peripheral PTP1B inhibitors in reduction of 





Obesity incidence is reaching epidemic proportions worldwide, and is associated with 
an increased risk of premature death [1,2]. As a consequence, the incidence of obesity-related 
disorders, such as metabolic syndrome, diabetes and cardiovascular disease, is rising at an 
alarming rate. A common feature of these disorders is the development of insulin resistance, 
resulting in decreased insulin-stimulated glucose uptake, failure to suppress hepatic glucose 
production, and accumulation of hepatic lipids. Obesity, in particular abdominal obesity, was 
pointed out as a primary contributor to acquired insulin resistance, as increasing adiposity is 
correlated with impaired insulin action [1,3].  
Growing evidence suggests that hepatic insulin resistance is sufficient to induce 
several components of the metabolic syndrome and promote progression to cardiovascular 
disease [1]. Vascular dysfunction related to obesity, in particular endothelial dysfunction in 
various vascular beds and in response to different vasodilator stimuli, might affect both 
peripheral vascular resistance and the delivery of substrates to metabolically active tissues, 
thereby contributing to both hypertension and metabolic abnormalities. Endothelial 
dysfunction is characterized by defects in the normal vasodilator response to mediators such 
as acetylcholine or to shear stress. It is considered as an independent predictor of 
cardiovascular events that has been consistently associated with obesity and the metabolic 
syndrome in a complex interplay with insulin resistance and inflammation. Deficiency of 
endothelial nitric oxide (NO) is believed to be the primary defect that links insulin resistance 
and endothelial dysfunction.  
The mechanisms linking insulin resistance to endothelial dysfunction remain not well 
understood. There is evidence to suggest that the direct effects of insulin on the endothelium 
or disrupted endothelial insulin signalling may disturb endothelial function. Insulin stimulates 
endothelial cell production of NO [4], and, therefore, insulin resistance at the level of the 
endothelium might be expected to be associated with decreased insulin-stimulated NO. 
Duncan et al. [5] demonstrated that transgenic mice with endothelium-targeted over-
expression of a dominant-negative mutant of human insulin receptor had a significant 
endothelial dysfunction, as evidenced by blunted aortic vasodilation in response to 
acetylcholine. The insulin receptor is a classic receptor tyrosine kinase and, as such, is 
inactivated by protein tyrosine phosphatases, notably the protein tyrosine phosphatase 
(PTP)1B [6]. PTP1B is also a negative regulator of leptin receptor signalling [7]. Whole-body 
PTP1B knockout studies in mice established PTP1B as a key negative regulator of body mass 
and insulin sensitivity. PTP1B−/− mice are lean, insulin sensitive, and have enhanced muscle 
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and liver insulin receptor phosphorylation [8,9]. Mice with brain-specific PTP1B−/− deficiency 
exhibit a similar phenotype to the global knockouts in terms of resistance to diet-induced 
obesity and enhanced insulin sensitivity, mostly due to central effect on leptin signalling [10]. 
Muscle-specific PTP1B deficient mice exhibit marked improvement in whole-body glucose 
homeostasis, without changes in body mass or adiposity as well as myeloid-cell specific 
knockouts [11]; whilst adipocyte-PTP1B deficient mice exhibit mild glucose intolerance and 
increased adipocyte cell size [12,13].  
Liver-specific PTP1B deletion (L-PTP1B-/-) improves whole-body glucose and lipid 
homeostasis, independently of changes in body mass/adiposity [14,15]. Liver-specific 
PTP1B−/− mice exhibit increased hepatic insulin signalling, enhanced insulin-induced 
suppression of hepatic glucose production in clamp studies and decreased expression of 
gluconeogenic genes. L-PTP1B-/- mice are also protected against HFD-induced increase in 
serum and liver triglyceride and cholesterol levels, associated with decreased expression of 
lipogenic genes [14,15]. Hepatic PTP1B may affect lipid metabolism via a pathway distinct 
from the insulin signalling where its location within the endoplasmic reticulum (ER) 
membrane appears critical. This was mainly attributable to L-PTP1B-/- mice being protected 
against obesity-induced ER stress in the liver [14,15]. ER stress has been reported to play a 
crucial role in insulin resistance and lipid accumulation [16].  
Considering that in vivo liver-PTP1B deficiency improves hepatic insulin sensitivity 
and both global glucose homeostasis and lipid metabolism independently of changes in 
adiposity and body mass, we hypothesized that liver-specific PTP1B deficiency would also 
lead to protection against obesity-induced endothelial dysfunction and reduction of 






All animal studies were performed under a project licence approved by the Home Office 
under the Animals (Scientific Procedures) Act 1986. Mice were maintained on a 12-hour 
light/dark cycle in a temperature-controlled barrier facility, with free access to water and food. 
L-PTP1B-/- mice were described previously and were achieved using an Albumin-cre 
promoter [14,15]. All mice studied were age-matched littermate males on the mixed 
129Sv/C57Bl6 background. Genotyping for the PTP1B floxed allele and the presence of 
Albumin-Cre was performed by PCR [14,17]. Mice were placed either on standard chow 
pellet diet (Rat and Mouse Breeder and Grower, Special Diets Services, Horley, UK) or high-
fat diet (HFD) (Adjusted Calories Diet, 55% Fat, Harlan Teklad, Belton, UK or Research 
Diets, 45% Fat) at weaning (21 days old), and weights were monitored weekly.   
Metabolic measurements 
Glucose from tail blood was assessed using a glucometer (Accu-Check, Burgess Hill, UK). 
Serum insulin was determined by ELISA (CrystalChem, Downers Grove, USA). Glucose 
tolerance tests (GTTs) were performed as described previously, following an overnight fast 
[12,14]. 
Blood Pressure 
Each mouse was trained to the tail-cuff technique for 2 days before each measurement was 
recorded with a Physiograph Desk Model and an Electro-Sphygmomanometer (LE 5001 non-
invasive blood pressure meter, Panlab, Barcelona, Spain). Five separate measurements were 
made on conscious mice for systolic and diastolic blood pressure (mmHg) and heart rate 
determinations. 
Echocardiographic examination 
In vivo transthoracic echocardiography was performed using a Vevo770 high frequency 
ultrasound machine (Visual Sonics, Toronto, Canada) in mice anesthetized with isoflurane 
(induction 5 %, maintenance 2 %) inhalation. Briefly, a two-dimensional short axis view of 
the left ventricle was obtained at the level of the papillary muscle in order to record M-mode 
tracings. Left ventricular end-diastolic diameter (LVEDD) and end-systolic diameter 
(LVESD) were measured by the American Society of Echocardiology leading-edge method 
from at least 3 consecutive cardiac cycles. Doppler cardiac output was calculated cardiac 
index was calculated by normalizing the cardiac output to the animal body weight as 




Mice were sacrificed and aorta removed and carefully cleaned of adhering fat and connective 
tissue and then cut into rings (1.5-2 mm long) that were mounted on a wire myograph filled 
with physiological salt solution (PSS), as previously described [18-20]. Endothelium-
dependent vasodilatation in response to acetylcholine (ACh, 1 nM to 10 µM, Sigma-Aldrich, 
St. Quentin, Fallavier, France) was studied in aortas with functional endothelium pre-
contracted with the thromboxane A2 agonist (9, 11-dideoxy-11a, 9a-
epoxymethanoprostaglandin F2-α) (U46619; Sigma-Aldrich, St. Quentin, Fallavier, France) at 
80% of their maximal response in the presence or absence of the superoxide dismutase (SOD) 
mimetic, Mn(III)tetrakis(1-Methyl-4-pyridyl)porphyrin Pentachloride (MnTMPyP; Sigma-
Aldrich, St. Quentin, Fallavier, France). 
Contractile response was assessed by concentration-response curves by cumulative 
application of serotonin (5-HT, 1 nmol/ to 10 µmol/l; Sigma-Aldrich, St. Quentin, Fallavier, 
France) to aortas with functional endothelium in the absence or presence the given inhibitor 
pre-incubated for 30 min: the NO synthase inhibitor NG-nitro-L-arginine (L-NA, 100 µmol/l; 
Sigma-Aldrich, St. Quentin, Fallavier, France), the selective cyclooxygenase (COX)-2 
inhibitor N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide (NS-398, 10 µmol/l; 
Sigma-Aldrich, St. Quentin, Fallavier, France), indomethacin, the non-selective COX 
inhibitor (100 µmol/l; Sigma-Aldrich, St. Quentin, Fallavier, France). All inhibitors were used 
at maximal active concentrations at which they inhibit the release of either NO from all 
isoforms of NO synthases, metabolites from COX-2 isoform or metabolites from COX in 
blood vessels, as reported in many of our previous studies [18-20]. Higher concentrations of 
L-NA, NS-398 or indomethacin did not induce further inhibition. 
Also, relaxation was assessed in response to sodium nitroprusside (SNP; Sigma-Aldrich, St. 
Quentin, Fallavier, France; 1 nM to 10 µM), a donor of NO in aorta rings pre-contracted with 
U46619. 
Determination of prostanoid production 
After sacrifice of mice, aorta was dissected and treated with 5-HT (1 µM, 37°C, 30 min; 
Sigma-Aldrich, St. Quentin, Fallavier, France) in 500 μL of PSS. After collection of the 
medium, prostacyclin, prostaglandin E and 8-isoprostane were measured by enzyme 
immunoassays kits (Cayman Chemicals, Ann Arbor, USA). The concentration of prostanoids 
was expressed as pg/ml/mg tissue (dry weight) [19]. 
Immunoblotting 
Tissue lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer as previously 
described [10,12,14]. Proteins were separated by 10% SDS-PAGE and transferred to 
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nitrocellulose membranes. Immunoblots were performed using antibodies against p-eNOS Ser 
1177, p-eNOS Thr 495 (Cell Signaling Technology, Beverly, USA), COX-1, COX-2, eNOS, 
iNOS, caveolin-1 (BD Biosciences, San Jose, USA), Cu/Zn-SOD, Mn-SOD, EC-SOD 
(Stressgen Biotechnologies; Victoria, Canada), SHP-2 (Santa Cruz  Biotechnology, Dallas, 
USA) and PTP1B (Abcam, Cambridge, UK). Immunoblots were developed with horseradish 
peroxidase-conjugated secondary antibody, visualized using enhanced chemiluminescence, 
and quantified by densitometry scanning. 
superoxide anion (O2−) determination by electron paramagnetic resonance (EPR) 
For superoxide anion (O2
-) spin-trapping, mouse aortas were dissected and allowed to 
equilibrate in deferoxamine-chelated Krebs-Hepes solution containing 1-hydroxy-
3methoxycarbonyl-2,2,5,5-tetramethylpyrrolidin (CMH, Noxygen; Denzlingen, Germany) 
(500 µM), deferoxamin (25 µM, Sigma-Aldrich, St. Quentin, Fallavier, France) and DETC (5 
µM, Sigma-Aldrich, St. Quentin, Fallavier, France) under constant temperature (37°C) for 60 
minutes. Then, they were frozen in liquid N2 and analyzed in a Dewar flask by EPR. Values 
are expressed in unit/mg weight of dried tissue [18,19]. 
Data analysis 
Data are expressed as mean ± SEM, and n represents the number of mice or biological 
replicates. Statistical analyses were performed using ANOVA (2-way or 1-way, as 






In vivo liver-PTP1B deficiency improves glucose and lipid homeostasis 
As expected from our previous findings, this cohort of L-PTP1B−/− mice exhibited ~80% 
decrease in PTP1B protein in whole liver lysates compared to control littermates (Figure 1A). 
However, aortas from L-PTP1B−/− and control (fl/fl) mice expressed PTP1B to the same level 
(Figure 1A). 
L-PTP1B−/− and control mice were weaned either onto normal chow diet (4.5% fat) or HFD 
(55% kcal from fat). There were no differences in body weight between the control and L-
PTP1B−/− mice on either diet (Figure 1B) and as previously published [14]. There was a 
tendency for L-PTP1B−/− mice to have a slightly higher body mass, but this was not 
significant at any point. HFD-feeding increased to the same extent liver weight (Figure 1C) in 
both L-PTP1B−/− and control mice, but did not affect heart weight in either genotype (Figure 
1D). 
To assess the efficiency of HFD to induce glucose intolerance, we performed longitudinal 
glucose tolerance tests (GTTs). As expected, HFD-fed control mice developed glucose 
intolerance in a time-dependent manner (Figure 1E and 1F), whilst L-PTP1B−/− mice 
exhibited an enhanced ability to clear glucose from the peripheral circulation during 
intraperitoneal GTTs (at both 5- and 12-weeks of HFD) (Figure 1E and 1F).  
By monitoring fasting glucose levels of L-PTP1B−/− and control littermates on HFD 
longitudinally, we determined that whilst at 5 weeks of HFD there were no differences in 
fasting glucose levels between the two groups, at 8 and 12 weeks of HFD-feeding control 
littermates developed fasting hyperglycemia (Figure 1G).  
L-PTP1B−/− mice had markedly lower circulating insulin levels (Figure 1H), under both chow- 
and HFD-feeding conditions. This was associated with an increase in serum cholesterol levels 
upon HFD-feeding in control mice only, whilst L-PTP1B−/− mice had the same cholesterol 
levels as chow-fed mice (Figure 1I).  
Collectively, these data indicate that, L-PTP1B−/− mice are protected against HFD-induced 
glucose intolerance and show improvements in lipid maintenance compared to their control 
littermates, like previously shown by us [14]. 
 
Liver-PTP1B deficiency protects against HFD-induced blood pressure increase and 
cardiac function alterations 
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Obesity is associated with hypertension and risk of developing cardiovascular disease 
[1,3,21]. To investigate the cardiovascular effects of liver-specific PTP1B deficiency in the 
context of obesity, blood pressure (BP) was monitored longitudinally in chow- and HFD-fed 
mice of both genotypes, using the non-invasive tail-cuff system. Prior to the terminal 
procedure, we performed the analysis of cardiac structure and function. 
Heart rate was unaffected by short-term (3 weeks) or long-term (10 and 14 weeks) 
HFD-feeding in either genotype (Figure 2A). Short-term HFD-feeding (3 weeks) did not 
affect systolic blood pressure in either group; however, longer-term HFD-feeding (10- and 
14-weeks) increased BP in both L-PTP1B-/- and control littermates; however, L-PTP1B-/- 
mice had significantly lower systolic BP compared to controls at both of these time-points 
(Figure 2B).  
Diastolic BP was comparable between the groups for the first 10 weeks of HFD-
feeding; however, whilst diastolic BP increased in the control fl/fl mice at 14 weeks post-
HFD feeding, L-PTP1B-/- mice were protected (Figure 2C). 
Next, we investigated by echocardiography the structure and function of the left 
ventricle of HFD-fed control and L-PTP1B−/− mice and compared it to their lean chow-fed 
respective controls. HFD-feeding increased systolic left-ventricular dimension (LVDs) in 
control fl/fl mice (Figure 2D), without affecting their diastolic left-ventricular dimension 
(LVDd) (Figure 2E). Interestingly however, HFD-feeding did not cause cardiac remodeling in 
L-PTP1B−/− mice, as measured by LVDs and LVDd (Figure 2D and 2E). Moreover, HFD-
feeding decreased cardiac index in control fl/fl mice only, whilst L-PTP1B−/− remained 
completely protected (Figure 2F). 
 
Liver-PTP1B deficiency protects against obesity-induced endothelial dysfunction in 
mouse aorta 
Endothelial dysfunction, a key early factor in the development of atherosclerosis and a 
predictor of cardiovascular events, has been found in patients with obesity and metabolic 
syndrome [20]. Thus, the effect of liver-PTP1B deficiency on endothelial function was 
evaluated in aortas isolated from mice fed chow or HFD. On chow diet, there were no 
differences between the L-PTP1B−/− and control littermates (Figure 3A). As expected, HFD-
feeding significantly impaired endothelium-dependent vaso-relaxation in response to 
acetylcholine in aortas collected from control fl/fl mice compared to chow diet-fed control 
fl/fl mice (Figure 3B). Remarkably, L-PTP1B−/− mice were completely protected against 
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HFD-induced endothelial dysfunction and remained as sensitive as chow-fed mice (Figure 
3C).  
To examine if the observed impaired response to acetylcholine in HFD-fed mice may 
be due to an impaired capacity of smooth muscle to dilate, the relaxation to an NO donor, 
SNP, was assessed in aortas from HFD-fed control fl/fl and L-PTP1B−/− mice. As shown in 
Figure 3D, response to SNP stimulation was similar in aortas from both control fl/fl and L-
PTP1B−/− mice, indicating the absence of alterations in the capacity of smooth muscle to 
dilate.  
Western blotting analyses demonstrated that HFD-feeding decreased eNOS 
phosphorylation at the activator site (Ser 1177) in aortas from both control fl/fl and L-
PTP1B−/− mice, but eNOS phosphorylation was significantly higher in aortas from L-
PTP1B−/− mice (Figure 4A). In addition, HFD-feeding enhanced, to the same extent, eNOS 
phosphorylation at the inhibitory site (Thr 495) in aortas from both control fl/fl and L-
PTP1B−/− mice (Figure 4B), without affecting total eNOS (Figure 4C), caveolin-1 (Figure 4D) 
or iNOS (Figure 4E) levels. 
 
Involvement of oxidative stress in HFD-induced endothelial dysfunction 
Endothelial dysfunction is associated with oxidative stress [22]. To assess whether the 
protective effect of liver-PTP1B deletion on endothelial function involves a decrease in 
reactive oxygen species (ROS), the endothelium-dependent relaxation in response to 
acetylcholine was evaluated in aortas from HFD-fed control fl/fl and L-PTP1B−/− mice in the 
presence of the cell-permeant SOD mimetic, MnTMPyP, to blunt superoxide anion (O2
-) 
production, the major ROS in vasculature.  
Even in the presence of MnTMPyP, the endothelial dysfunction still persisted in 
vessels from control fl/fl mice only (Figure 5A), indicating that ROS may not be involved in 
the mechanism of protection in L-PTP1B−/− mice.  
This was further confirmed by the absence of differences in O2
- production in aortas 
from all groups (Figure 5B). Assessment of protein levels of the different isoforms of 
antioxidant SOD enzyme (Mn-, EC-, and Cu/Zn-SOD) demonstrated that Mn- and EC-SODs 
levels were not affected, whilst Cu/Zn-SOD was increased in aortas from PTP1B−/− mice 
under HFD condition (Figure 5C-5E). 
 
Enhanced release of COX-derived vasodilators in aortas from L-PTP1B−/− mice 
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Vascular inflammation is reported to play a key role in obesity-induced vascular 
dysfunction [23]. Thus, the impact of HFD-feeding on vascular reactivity in response to 
vasoconstrictor agents was investigated with special emphasis on the relative contribution of 
inflammatory COX-derived agents in the regulation of vascular tone in both control fl/fl and 
L-PTP1B−/− mice, fed chow or HFD.  
Concentration-response curves in response to serotonin (5-HT) were constructed in 
aortas from control fl/fl and L-PTP1B−/− mice in the presence or absence of COX inhibitors. 
In the absence of any inhibitor, aortas from HFD-fed mice displayed a trend towards 
enhanced response to 5-HT compared to those examined from chow-fed groups (Figure 6A).  
The non-selective inhibition of COX isoforms by indomethacin blunted, to the same extent, 
the contractile response to 5-HT in aortas from all the groups (Figure 6B). Interestingly, 
however, the selective inhibition of COX-2 isoform, achieved using NS-398, decreased 
contractile response only in vessels from control fl/fl mice whilst the latter was preserved in 
vessels obtained from L-PTP1B−/− mice (Figure 6C). This indicated either a presence of more 
COX-2-derived vasoconstrictor agents in control fl/fl mice and/or secretion of more COX-2-
derived vasodilator agents in L-PTP1B−/− mice. 
To investigate this, we analyzed COX-derived metabolite release from mouse aortas in 
all the experimental groups, which revealed that both chow- and HFD-fed L-PTP1B−/− mice 
exhibited higher levels of prostacylin, a vasodilator metabolite (Figure 6D).  In addition, and 
as shown in Figure 6E, HFD-fed control fl/fl mice had higher levels of prostaglandin E, a 
vasoconstrictor metabolite, compared to chow–fed mice, whilst L-PTP1B−/− mice were 
completely protected.  
The vasoconstrictor metabolite isoprostane-8 release was unaltered in all the groups 
(Figure 6F). Furthermore, these effects are independent of changes in COX-1 levels (Figure 
6G and 6H); however, aortas from HFD-fed L-PTP1B−/− mice had increased protein levels of 





We have previously shown that selectively deleting PTP1B in mouse liver results in 
improved glucose homeostasis and decreased levels of triglycerides and cholesterol, 
independently of changes in body weight or adiposity [14,24]. More recently, we also 
demonstrated that inflammatory ER-stress response and hepatic PTP1B expression are 
interlinked and that directly down-regulating PTP1B expression in liver can relieve over-
activation of the ER-stress response associated with HFD-feeding, obesity and insulin 
resistance [15,16]. We now report that these improvements in hepatic insulin sensitivity in L-
PTP1B−/− mice can also lead to a complete protection against obesity-induced endothelial 
dysfunction and cardiovascular remodelling, at least partly due to a further modulation of the 
relative contribution of COX-derived vasodilator agents in the regulation of vascular tone. 
Altogether, these studies show a complex interplay between obesity, hepatic insulin resistance 
and cardiovascular dysfunction and indicate that liver-PTP1B deficiency is able to improve 
several features of metabolic syndrome and thus highlight the potential utility of PTP1B 
inhibitors not only as anti-diabetic drugs but also as useful agents to protect against 
cardiovascular disease.  
One of the major findings in the present work is that liver-PTP1B deletion protected 
mice in vivo against obesity-induced blood pressure increase and functional alterations of left 
ventricle, and improved glucose homeostasis at the same time. These data are consistent with 
observations in the literature associating impaired cardiac function with poor insulin 
sensitivity. Diabetes and insulin resistance often coexist with chronic heart failure in an inter-
relationship such that each condition may impact on each other in terms of causation and 
outcome. In the Framingham study, Kannel et al. reported that nearly 20% of patients with 
chronic heart failure also had diabetes [25]. L-PTP1B-/- mice protection against HFD-induced 
increase in systolic and diastolic blood pressure and remodelling at the left ventricle level, 
was most likely due to the correction of peripheral insulin resistance in cardiac tissue. These 
findings are in line with a previous study from our group showing that treatment of Zucker 
fatty obese rats with red-wine polyphenol extract reduced glycaemia and blood pressure and 
improved left ventricle cardiac performances in obese rats [18]. Together with the current 
findings, these results reinforce the critical role of new insulin sensitizing approaches in 
correcting cardiac dysfunction associated with insulin resistance in cardiac tissue.  
Other insulin sensitising strategies, however, were notable to correct cardiac 
alterations associated with insulin resistance. For instance, thiazolidinediones were reported to 
improve insulin sensitivity in the liver and peripheral tissues [26]; however, adverse 
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cardiovascular outcomes were also reported to be associated with the use of 
thiazolidinediones, most notably with chronic heart failure hospitalizations [27]. Liver-PTP1B 
targeting and its subsequent improvement of insulin sensitivity may lead to improved 
myocardial energy metabolism and thus to improved cardiac function [28]. Together these 
findings position the targeting of liver-PTP1B as a new and safe potential therapeutic 
approach to reduce both insulin resistance and cardiac disturbances associated to it.  
Targeting directly PTP1B at the whole-body level either by genetic deletion in mouse 
or using pharmacological inhibitors was also shown to reduce adverse left ventricle 
remodelling, and to improve left ventricle function in a mouse model of chronic heart failure 
[29]. Nonetheless, because total PTP1B-/- mice are lean and resistant to obesity and 
dramatically insulin and leptin sensitive, and because of the systemic action of PTP1B 
inhibitors, it is very difficult to conclude from this study whether the observed effects are 
secondary to the global enhanced insulin sensitivity or a direct effect of PTP1B-deletion in the 
cardiovascular tree. The present findings suggest improvements in hepatic and global insulin 
sensitivity that can directly lead to an improvement in cardiac function in L-PTP1B-/- mice. 
These effects occur without affecting PTP1B in endothelial cells or cardiomyocytes and lead 
to protection against cardiovascular disease. 
The present study showed that liver-PTP1B deletion was protective against obesity-
induced endothelial dysfunction, an early step in development of atherosclerosis. Endothelial 
dysfunction was described to be inextricably associated with obesity and insulin resistance.  
Indeed, insulin receptors are present in endothelial cells and the disruption of endothelial 
insulin signalling may affect endothelial function [4,30]. At physiological concentrations, 
insulin stimulates both eNOS activity and expression in endothelial cells [31,32]. The 
phosphorylation of eNOS at Ser 1177 can be blunted by hyperglycaemia [33] and elevated 
concentrations of saturated free fatty acids under conditions of vascular insulin 
resistance [34]. In the present study, diet-induced obesity blunted the phosphorylation of 
eNOS at Ser 1177 in aortas from control mice while it was partially restored in vessels from 
L-PTP1B-/- mice most probably due to enhanced insulin sensitivity. Interestingly, the HFD-
induced endothelial dysfunction was not associated with an increase in oxidative stress. In our 
study, mainly the contribution of superoxide anion was assessed, but other free radicals such 
as peroxynitrite may also play a role in the observed endothelial dysfunction [35]. It was 
shown that in HFD-fed L-PTP1B−/− mice, vascular Cu/Zn-SOD expression was increased 
while the superoxide production was not altered. These data may suggest that increased 
antioxidant defense mechanism participate to decrease oxidative stress in these animals. Thus 
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decrease and/or normalization of oxidative stress might be responsible for most of the 
cardiovascular protection in the current study.  
Interestingly, aortas from HFD-fed L-PTP1B-/- had a fully preserved vasoconstrictor 
response to 5-HT in the presence of COX-inhibitors. This was associated with reduced levels 
of COX-derived vasoconstrictors (prostaglandin E) and enhanced production of vasodilators 
(prostacyclins) owing to an increase in COX-2 levels. The reduction in the secretion of 
prostacyclin together with NO by the endothelium forms the basis of endothelial abnormality 
in diabetes. Clinical and experimental diabetes are associated with a reduction in prostacyclin 
secretion [36,37]. The increased level of prostacyclin is thus a compensatory mechanism 
which may participate in maintaining endothelium-dependent relaxation within physiological 
range in aortas from L-PTP1B-/- mice. Consistent with the present findings, previous studies 
indicated that COX-2 protein levels are elevated in the aortas of mice with obesity and type 2 
diabetes [38]. In addition, in diabetic patients, vascular expression of COX-2 was found to be 
markedly elevated in coronary arterioles and bradykinin induced enhanced COX-2-derived 
prostaglandin-mediated dilation in these vessels [39]. Furthermore, in L-PTP1B-/- mice, 
improved left ventricle function may lead to improved haemodynamics and thus participate in 
the improvement of endothelial function through for example an increase in vascular shear 
stress. It has previously been reported that insulin resistance decreases activity of arterial 
prostacyclin synthase, the key enzyme involved in prostanoid biosynthesis of prostacyclin, by 
increasing endothelial fatty acid oxidation [40]. Here, we report that liver-PTP1B deletion 
improved whole-body insulin resistance and lipid metabolism in addition to decreasing ER 
stress response, as previously reported by us [14,15]. Altogether, these effects may improve 
the activity of prostacyclin synthase thus leading to increased levels of vascular prostacylin 
release. 
Several studies have reported that direct whole-body targeting of PTP1B improved 
endothelial function in different cardiovascular disease animal models of obesity and chronic 
heart failure [29,41,42]. Ali et al. [41] demonstrated that total PTP1B knock-down improved 
endothelial function in peripheral vessels from obese and diabetic leptin-receptor deficient 
db/db mice.  Gomez et al. [29] and Vercauteren et al. [42] reported in mouse models of 
chronic heart failure that both genetic deletion and pharmacological inhibition of PTP1B 
improved flow-mediated dilation in small mesenteric arteries. However, these experimental 
models do not allow to distinghish whether this improvement is due to global enhancement of 
insulin sensitivity or due to PTP1B deletion in endothelial cells themselves because of the 
systemic targeting of PTP1B in these animals. Indeed, these findings may reflect a direct role 
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of PTP1B in the endothelium with special emphasis on eNOS activation and NO release, 
through enhanced tyrosine phosphorylation of eNOS. Activation of eNOS by shear stress was 
indeed shown to require tyrosine phosphorylation [43] in addition to the classical 
phosphorylation pattern on Ser 1177. The generation of endothelium-specific PTP1B 
knockouts will help addressing these conflicting mechanistic points.  
Finally, inflammatory signalling was not assessed in the present study that may 
contribute to endothelial dysfunction. However, very recently, it has been reported that 
PTP1B deletion protects against septic-shock-induced cardiovascular function resulting from 
reduction of inflammation [44]. Such mechanism might be also implicated in the 
improvement of endothelial dysfunction reported here. Furthermore, we have previously 
shown that because of its critical localisation within the ER membrane liver-PTP1B deletion 
decreased ER stress response [14,15], which has been reported to play a crucial role in insulin 
resistance and lipid accumulation [16] and more recently was shown to play an important role 
in endothelial dysfunction in experimental models of diabetes and hypertension [45,46]. 
Diagram shown in Figure 7 summarizes the main mechanisms behind improved 
cardiovascular function in L-PTP1B-/- mice.  
Altogether, our findings further demonstrate the critical role of PTP1B in hepatic 
glucose and lipid metabolism and underscore the importance of targeting liver-PTP1B as a 
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Figure Legends  
Figure 1. In vivo liver-PTP1B deletion improves glucose and lipid homeostasis 
independently of body mass changes 
(A) PTP1B protein levels in livers (n = 3) and aortas (n = 6) from fl/fl control and L-PTP1B-/- 
mice. (B)  
Terminal body weights of fl/fl control and L-PTP1B-/- mice fed either chow or high fat diets. 
(C) Terminal liver weights from fl/fl control and L-PTP1B-/- mice fed either chow or high fat 
diets. (D) Terminal heart weights from fl/fl control and L-PTP1B-/- mice fed either chow or 
high fat diets. (E) GTTs in fl/fl control and L-PTP1B-/- mice at 5 weeks of HFD. (F) GTTs in 
fl/fl control and L-PTP1B-/- mice at 12 weeks of HFD. (G) Fasting blood glucose in fl/fl 
control and L-PTP1B-/- mice at 5, 8 and 12 weeks of HFD. (H) Fasting insulin levels in fl/fl 
control and L-PTP1B-/- mice fed either chow or high fat diets. (I) Total cholesterol circulating 
levels in fl/fl control and L-PTP1B-/- mice fed either chow or high fat diets. Data are presented 
as mean± SEM and were analysed by either by one-way or two-way (E, F) ANOVA or one-
way ANOVA, followed with a Tukey’s multiple comparison test. *P<0.05, **P<0.01, 
***P<0.001 vs. the indicated group or chow fl/fl and ## P < 0.01 vs. chow L-PTP1B-/- (n = 7-
11 in each group). 
Figure 2. Liver-PTP1B deletion protects against obesity-induced blood pressure increase 
and cardiac function alterations 
(A) Heart rate in fl/fl control and L-PTP1B-/- mice at 5, 10 and 14 weeks of HFD. (B) Systolic 
blood pressure in fl/fl control and L-PTP1B-/- mice at 5, 10 and 14 weeks of HFD. (C) 
Diastolic blood pressure in fl/fl control and L-PTP1B-/- mice at 5, 10 and 14 weeks of HFD. 
(D) End-Systolic left ventricle (LV) dimension in in fl/fl control and L-PTP1B-/- mice fed 
either chow or high fat diets. (E) End-Diastolic left ventricle (LV) dimension in in fl/fl control 
and L-PTP1B-/- mice fed either chow or high fat diets. (F) Cardiac index (CI) in fl/fl control 
and L-PTP1B-/- mice fed either chow or high fat diets. Data are presented as mean± SEM and 
were analysed by one-way ANOVA, followed with a Tukey’s multiple comparison test. 
*P<0.05, ***P<0.001 vs. 3 weeks HFD or chow mice; #P<0.05 vs. fl/fl mice in the same 
group. (n = 7-11 in each group). 
Figure 3. Liver-PTP1B deletion protects against obesity-induced endothelial dysfunction 
in mouse aorta 
(A) Endothelium-dependent relaxation in response to ACh in aortas from fl/fl control and L-
PTP1B-/- mice fed chow diet. (B) Endothelium-dependent relaxation in response to ACh in 
aortas from fl/fl control mice fed either chow or high fat diets. (C) Endothelium-dependent 
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relaxation in response to ACh in aortas from fl/fl control and L-PTP1B-/- mice fed HFD. (D) 
Endothelium-independent relaxation in response to SNP in aortas from fl/fl control and L-
PTP1B-/- mice fed. Data are presented as mean± SEM and were analysed by two-way 
ANOVA. **P<0.01, ***P<0.001 vs. indicated group. (n = 7-11 in each group). 
Figure 4. Altered eNOS signalling in mouse aorta from L-PTP1B−/− mice (A) 
Phosphorylation of eNOS on activator site Ser 1177 in aortas from fl/fl control and L-PTP1B-
/- mice fed either chow or high fat diets. (B) Phosphorylation of eNOS on inhibitor site Thr 
495 in aortas from fl/fl control and L-PTP1B-/- mice fed either chow or high fat diets. (C) 
Total eNOS expression in aortas from fl/fl control and L-PTP1B-/- mice fed either chow or 
high fat diets. (D) Caveolin-1 expression in aortas from fl/fl control and L-PTP1B-/- mice fed 
either chow or high fat diets. (E) iNOS expression in aortas from fl/fl control and L-PTP1B-/- 
mice fed either chow or high fat diets. Western blots results are representative of 3 
independent experiments (n = 3 mice in each group), and the densitometry values are 
expressed in arbitrary units (A.U.). Data are presented as mean± SEM and were analysed by 
one-way ANOVA, followed with a Tukey’s multiple comparison test. **P<0.01vs. chow 
groups and #P<0.05 vs. the indicated group.  
Figure 5. Oxidative stress in not involved in obesity-induced endothelial dysfunction in 
mouse aorta 
(A) Endothelium-dependent relaxation in response to ACh in the presence of SOD mimetic 
(MnTMPyP) in aortas from fl/fl control and L-PTP1B-/- mice fed HFD. (B) Superoxide anion 
(O2
-) production in aortas from fl/fl control and L-PTP1B-/- mice fed either chow or high fat 
diets. Mn SOD (C), EC SOD SOD (D) and Cu/Zn (E) expressions in aortas from fl/fl control 
and L-PTP1B-/- mice fed either chow or high fat diets. Western blots results are representative 
of 3 independent experiments (n = 3 mice in each group), and the densitometry values are 
expressed in arbitrary units (A.U.). Data are presented as mean± SEM and were analysed 
either by two-way ANOVA (A) or one-way ANOVA, followed with a Tukey’s multiple 
comparison test (B-E). *P<0.05vs. fl/fl mice. 
Figure 6. Enhanced release of COX-2 derived vasodilators in aortas from L-PTP1B−/− 
mice 
(A) Vascular reactivity in response to 5-HT agonist in aortas from fl/fl control and L-PTP1B-/- 
mice fed either chow or high fat diets. (B) Vascular reactivity in response to 5-HT agonist in 
the presence of non-selective COX inhibitor, indomethacin, in aortas from fl/fl control and L-
PTP1B-/- mice fed either chow or high fat diets. (C) Vascular reactivity in response to 5-HT 
agonist in the presence of COX-2 selective inhibitor, NS398, in aortas from fl/fl control and 
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L-PTP1B-/- mice fed either chow or high fat diets. (D) Prostacyclin release in aortas from fl/fl 
control and L-PTP1B-/- mice fed either chow or high fat diets. (E) Prostaglandin E release in 
aortas from fl/fl control and L-PTP1B-/- mice fed either chow or high fat diets. (F) 8-
Isoprostane release in aortas from fl/fl control and L-PTP1B-/- mice fed either chow or high fat 
diets. (G) COX-1 and COX-2 protein expressions in aortas from fl/fl control and L-PTP1B-/- 
mice fed either chow or high fat diets. Western blots results are representative of 3 
independent experiments (n = 3 mice in each group), and the densitometry values are 
expressed in arbitrary units (A.U.). Data are presented as mean± SEM and were analysed 
either by or two-way ANOVA (A-C) or one-way ANOVA followed with a Tukey’s multiple 
comparison test (D-H). *P<0.05, **P<0.01, ***P<0.001vs. the indicated group or fl/fl mice.  
 
Figure 7. Summary of mechanisms involved in cardiovascular liver-PTP1B actions 
Obesity leads to an increase in the expression and activity of PTP1B in the liver which will 
then cause hepatic insulin resistance through the inactivation of insulin receptor signalling 
pathway. Furthermore, because of its critical localisation within the endoplasmic reticulum 
(ER) membrane, PTP1B will also lead to activation of the ER stress response pathway, 
leading to lipid accumulation and activation of inflammatory pathways. Altogether, impaired 
hepatic glucose homeostasis and increased lipid metabolism in addition to ER stress 
activation will eventually cause endothelial dysfunction in peripheral vessels and impair 
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